How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

897 results for

Medication Causes of Dyspepsia


Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. MASCC and ESMO Consensus Guidelines for the Prevention of Chemotherapy and Radiotherapy-Induced Nausea and Vomiting

,TheNetherlands introduction Despite the considerable progress achieved in the last 30 years, vomiting and, especially, nausea, continue to be twoof the most distressing side-effects of cancer chemotherapy. In the late 1990s, several professional organisations published recommen- dations on the optimal antiemetic prophylaxis in patients sub- mitted to chemotherapy and/or radiotherapy. The European Society of Medical Oncology (ESMO) and the Multinational Association of Supportive Care in Cancer (MASCC (...) with ondansetron plus dexamethasone (48% versus 12%) [59]. The second trial compared ondansetron plus aprepitant with/ Volume27 | Supplement5 | September2016 doi:10.1093/annonc/mdw270 | v??? AnnalsofOncology clinicalpracticeguidelineswithout dexamethasone versus ondansetron plus placebo with/ without dexamethasone [60]. A complete response rate (no vomiting, no retching and no use of rescue medications) of 65% was reported in the ondansetron plus aprepitant arm versus 51% in the ondansetron arm for the ?rst 24

2017 European Society for Medical Oncology

122. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients

, 4, 6962 Viganello-Lugano, Switzerland. E-mail: and/or to The MASCC Office. E-mail: Search for other works by this author on: R. J. Gralla 5Albert Einstein College of Medicine, Jacobi Medical Center, New York * Correspondence to: c/o ESMO Guidelines Committee, ESMO Head Office, Via Luigi Taddei, 4, 6962 Viganello-Lugano, Switzerland. E-mail: and/or to The MASCC Office. E-mail: Search for other works by this author on: E. Bruera 6Department of Palliative, Rehabilitation and Integrative Medicine (...) , Johannesburg, South Africa * Correspondence to: c/o ESMO Guidelines Committee, ESMO Head Office, Via Luigi Taddei, 4, 6962 Viganello-Lugano, Switzerland. E-mail: and/or to The MASCC Office. E-mail: Search for other works by this author on: J. Roscoe 15Department of Surgery, University of Rochester Medical Center, Rochester, USA * Correspondence to: c/o ESMO Guidelines Committee, ESMO Head Office, Via Luigi Taddei, 4, 6962 Viganello-Lugano, Switzerland. E-mail: and/or to The MASCC Office. E-mail: Search

Full Text available with Trip Pro

2016 International Society for Oral Oncology

123. Lymphangioleiomyomatosis Diagnosis and Management Part I: An Official ATS/JRS Clinical Practice Guideline

reported to recur in transplanted lungs, consistent with a metastatic mechanism for the disease (14, 15), but has not been reported to cause graft failure or to jeopardize eligibility for transplant. Genetic studies have revealed clonal origins for neoplastic cells harvested from pulmonary and extrapulmonary lesions of individual patients (16, 17). The neoplastic cells that in?ltrate the lung in patients with LAM have smooth muscle characteristics and a benign histological appearance (18), arise from (...) , important, or not important (27). LiteratureSearchandStudySelection In collaboration with an ATS methodologist (J.L.B.), a search strategy was designed using medical subject heading keywords and text words. The searches were limited to human studies and articles in English or in any language with English abstracts. A librarian from the National Institute of Health (K.S.) performedtheinitialliteraturesearchin2009. Four databases were searched: MEDLINE, EMBASE, Web of Science, and Scopus. AMERICAN

2016 American Thoracic Society

124. Management of Acute and Recurrent Gout: A Clinical Practice Guideline from the American College of Physicians

in patients with acute gout. These drugs have known anti-inflammatory activity and have been shown to reduce pain in many conditions. Further, they have been successfully used to prevent gout flares during urate-lowering therapy. The main harms of NSAIDs are gastrointestinal adverse effects ranging from minor (dyspepsia) to serious (perforations, ulcers, and bleeding). Long-term use of higher doses can cause chronic renal insufficiency. Corticosteroids There were no placebo-controlled trials of oral (...) publication, or once an update has been issued. Disclaimer: The authors of this article are responsible for its contents, including any clinical or treatment recommendations. Financial Support: Financial support for the development of this guideline comes exclusively from the ACP operating budget. Disclosures: Dr. Barry reports grants and personal fees from the Informed Medical Decisions Foundation and Healthwise outside the submitted work. Dr. Boyd reports royalties from UpToDate outside the submitted

Full Text available with Trip Pro

2016 American College of Physicians

125. Screening and Management of Lipids

obtaining data. Assess ASCVD risk factors • Clinical atherosclerotic cardiovascular disease (ASCVD includes stroke; peripheral arterial disease; coronary heart disease). • LDL-C = 190 mg/dL and age = 21,not caused by drugs or underlying medical condition (Table 1). • Diabetes mellitus type 1 or 2, age 40-75 years of age with LDL-C 70-189 mg/dL. • 10-year ASCVD risk = 7.5% for ages 40-75years (see Table 2 for calculation information). • CKD.(If CKD, see the UMHS CKD guideline for managing lipids in CKD (...) , but have had no effect on mortality, and in some instances have been associated with increased adverse events. For this reason, they are considered second line medications for CHD prevention and are primarily reserved for patients with severe triglyceride elevation (> 500 mg/dl) despite lifestyle changes to prevent pancreatitis. Adverse effects are generally GI, including nausea, dyspepsia, and change in bowel habits. The risk of cholestasis and cholecystectomy is increased. Fibrates carry a small risk

2016 University of Michigan Health System

126. Laparoscopic insertion of a magnetic titanium ring for gastro-oesophageal reflux disease

(GORD) is a common problem. It is caused by conditions that disturb the sphincter function at the lower end of the oesophagus, such as a hiatus hernia. Symptoms of GORD can be broadly grouped into those directly related to reflux episodes, such as heartburn, regurgitation, chest pain and nausea, and those caused by complications of the disease, including dysphagia and respiratory difficulties. Repeated episodes of GORD can damage the lining of the oesophagus and lead to oesophageal ulceration (...) , oesophageal stricture and Barrett's oesophagus. Laparoscopic insertion of a magnetic titanium ring for gastro-oesophageal reflux disease (IPG585) © NICE 2018. All rights reserved. Subject to Notice of rights ( conditions#notice-of-rights). Page 2 of 82.2 A NICE clinical guideline describes recommendations for the investigation and management of GORD and dyspepsia in adults. The standard treatments for symptomatic GORD are lifestyle modification and drug therapy. Patients

2017 National Institute for Health and Clinical Excellence - Interventional Procedures

127. Myocardial infarction: cardiac rehabilitation and prevention of further MI

Is treatment with an oral anticoagulant, aspirin and clopidogrel preferable to treatment with an oral anticoagulant and clopidogrel in people who have had an MI, have an indication for oral anticoagulation and are treated either medically, by primary PCI or by coronary artery bypass grafting surgery? 26 2.4 What characteristics are associated with uptake and adherence to cardiac rehabilitation after an acute MI when rehabilitation is started early? 26 2.5 In people who have had a STEMI who undergo primary (...) guidance 80. The recommendations are labelled according to when they were originally published (see About this guideline for details). Myocardial infarction (MI) is one of the most dramatic presentations of coronary artery disease. It is usually caused by blockage of a coronary artery producing tissue death and consequently the typical features of a heart attack: severe chest pain, changes on the electrocardiogram (ECG), and raised concentrations of proteins released from the dying heart tissue

2013 National Institute for Health and Clinical Excellence - Clinical Guidelines

128. Idiopathic pulmonary fibrosis in adults: diagnosis and management

be documented. See the General Medical Council's Good practice in prescribing and managing medicines and devices for further information. Where recommendations have been made for the use of drugs outside their licensed indications ('off-label use'), these drugs are marked with a footnote in the recommendations. Idiopathic pulmonary fibrosis in adults: diagnosis and management (CG163) © NICE 2018. All rights reserved. Subject to Notice of rights ( conditions#notice-of-rights (...) :// conditions#notice-of-rights). Page 7 of 22Best supportive care Offer best supportive care to people with idiopathic pulmonary fibrosis from the point of diagnosis. Best supportive care should be tailored to disease severity, rate of progression, and the person's preference, and should include if appropriate: information and support (see recommendation 1.3.1) symptom relief management of comorbidities withdrawal of therapies suspected to be ineffective or causing harm end of life

2013 National Institute for Health and Clinical Excellence - Clinical Guidelines

129. Trastuzumab (Ogivri) - breast cancer or stomach cancer

infusion only. If an alternate route of administration is required, other trastuzumab products offering such an option should be used In order to prevent medication errors it is important to check the vial labels to ensure that the medicinal product being prepared and administered is trastuzumab and not trastuzumab emtansine. 4 Posology Metastatic breast cancer Three-weekly schedule The recommended initial loading dose is 8 mg/kg body weight. The recommended maintenance dose at three-weekly intervals (...) 2 ). The incidence of symptomatic cardiac dysfunction was 1.7 % in the trastuzumab arm. Clinical experience is limited in patients above 65 years of age. Infusion-related reactions (IRRs) and hypersensitivity Serious IRRs to trastuzumab infusion including dyspnoea, hypotension, wheezing, hypertension, bronchospasm, supraventricular tachyarrhythmia, reduced oxygen saturation, anaphylaxis, respiratory distress, urticaria and angioedema have been reported (see section 4.8). Pre-medication may

2019 European Medicines Agency - EPARs

130. Obese, overweight with risk factors: liraglutide (Saxenda)

with severe hepatic impairment, people with congestive heart failure class III to IV and people with obesity secondary to endocrine or eating disorders or obesity caused by another medicinal treatment. The SPC also recommends that liraglutide is not recommended for use in people with inflammatory bowel disease and diabetic gastroparesis. See the liraglutide (Saxenda) SPC for further details. The following are reported as very common (1 in 10 or more) adverse reactions in the liraglutide (Saxenda) SPC (...) : nausea, vomiting, diarrhoea and constipation. Common adverse reactions (from 1 in 100 to 1 in 10) reported in the SPC include hypoglycaemia, insomnia, dizziness, dysgeusia, dry mouth, dyspepsia, gastritis, gastro-oesophageal reflux disease, flatulence, eructation, upper abdomen pain, abdomen distension, cholelithiasis, injection site reactions, asthenia, fatigue, increased lipase and increased amylase. The EPAR for liraglutide (Saxenda) reported that the general adverse event profile is in-line

2017 National Institute for Health and Clinical Excellence - Advice

131. Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates

gastrointestinal adverse effects than intravenous bisphosphonates and some people may find them difficult to swallow. Nevertheless, some people may prefer oral medication because a hospital visit is not required. Zoledronic acid is administered intravenously and, it may be easier for some people to adhere to 6-monthly intravenous treatment, rather than daily oral treatment. Zoledronic acid infusion can cause an acute response resulting in flu-like symptoms. Calcium and vitamin D supplementation is generally (...) mortality (absolute reductions 1.4%, 1.1% and 1.7% respectively), but not breast cancer recurrence or all-cause mortality. When prespecified subgroup analyses according to menopausal status were undertaken, no benefits were seen in premenopausal women, but the benefits in postmenopausal women were found to be greater than in the general study population. At 10 years compared with control, the absolute reductions in the risk of breast cancer mortality, bone recurrence and all-cause mortality

2017 National Institute for Health and Clinical Excellence - Advice

132. Management of osteoporosis and the prevention of fragility fractures

in Scotland. The majority of fractures occur in people over the age of 65 and a large proportion of these patients have osteoporosis. Fractures are an important cause of morbidity, and patients who suffer hip fractures and vertebral fractures have a decreased life expectancy compared with population-based controls. A wide range of treatments that can reduce the risk of fractures occurring in patients with osteoporosis is now available. These have the potential to improve clinical outcomes for patients (...) with osteoporosis and to reduce societal costs of medical care associated with fractures. 1.2 REMIT of THE GuIDElINE 1.2.1 OvERALL OBjECTIvES This guideline provides recommendations based on current evidence for best practice in the management of osteoporosis and prevention of fractures. It addresses risk factors for fracture, commonly-used tools for assessment of fracture risk, approaches to targeting therapy, pharmacological, and non-pharmacological treatments to reduce fracture risk, treatment of painful

2015 SIGN

133. Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain. (PubMed)

Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain. There is increasing focus on providing high quality care for people at the end of life, irrespective of disease or cause, and in all settings. In the last ten years the use of care pathways to aid those treating patients at the end of life has become common worldwide. The use of the Liverpool Care Pathway in the UK has been criticised. In England the LCP (...) journal publication articles.Two review authors independently extracted adverse event data, and examined issues of study quality. The primary outcomes sought were numbers of participants experiencing adverse events of reduced consciousness, appetite, and thirst. Secondary outcomes were possible surrogate measures of the primary outcomes: delirium, dizziness, hallucinations, mood change and somnolence relating to patient consciousness, and nausea, vomiting, constipation, diarrhoea, dyspepsia, dysphagia

2014 Cochrane

134. Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) - Addendum to Commission A17-35

ACT appropriate comparator therapy AE adverse event CHC chronic hepatitis C CI confidence interval DAA direct acting antiviral agent G-BA Gemeinsamer Bundesausschuss (Federal Joint Committee) IQWiG Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency in Health Care) MedDRA Medical Dictionary for Regulatory Activities NS5A non-structural protein 5A PT Preferred Term RCT randomized controlled trial RR relative risk SAE serious adverse event SOC (...) study nor for the POLARIS-4 study presented as additional information. The reason was that the company had not presented the analyses of all AEs by System Organ Class (SOC) and Preferred Terms (PTs) according to the Medical Dictionary for Regulatory Activities (MedDRA) for the corresponding subpopulations. With its comments, the company subsequently submitted corresponding analyses at SOC and PT level for AEs and serious AEs (SAEs). Concurring with the methods described in the dossier assessment [1

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

135. Milk Thistle (PDQ®): Health Professional Version

thistle or silymarin primarily in individuals with or , although small studies have been reported about individuals with , , , , and . Few adverse have been reported for milk thistle, but little information about interactions with anticancer medications, , or other drugs is available. Milk thistle is available in the United States as a . Many of the medical and scientific terms used in this summary are hypertext linked (at first use in each section) to the , which is oriented toward nonexperts. When (...) in the specified amounts. The FDA has not approved the use of milk thistle as a treatment for patients or patients with any other medical condition. Despite milk thistle’s long history of being used to treat and complaints, it was not until 1968 that silymarin was isolated from the seeds of the plant, and it was proposed that silymarin might be the active ingredient.[ ] Researchers have investigated the role that silibinin may play in the treatment of and . Most studies have investigated the isolated compound

2018 PDQ - NCI's Comprehensive Cancer Database

136. Cartilage (Bovine and Shark) (PDQ®): Health Professional Version

is no longer being updated and is provided for reference purposes only. This information summary provides an overview of the use of as a treatment for people with cancer. The summary includes a brief history of cartilage research, the results of , and possible of cartilage use. This summary contains the following key information: Bovine (cow) cartilage and shark cartilage have been studied as treatments for people with cancer and other medical conditions for more than 30 years. Numerous cartilage products (...) , and the results are inconclusive. Additional of cartilage as a treatment for people with cancer are now being conducted. Many of the medical and scientific terms used in this summary are hypertext linked (at first use in each section) to the , which is oriented toward nonexperts. When a linked term is clicked, a definition will appear in a separate window. Reference citations in some cancer information summaries may include links to external websites that are operated by individuals or organizations

2018 PDQ - NCI's Comprehensive Cancer Database

137. Autosomal Dominant Polycystic Kidney Disease - Management of Polycystic Liver Disease

,some,mainlythose with severe cystic liver disease, have abdominal pain or swelling, and, less commonly, dyspepsia, early satiety, dyspnea, and back pain. The severity of cystic liver disease can be assessed by magnetic resonance imaging (MRI), based on total cyst number or total liver volume. 5 Complications such as hepatic cyst infection and bleeding cause pain acutely, and are not uncommon, occurring in at least 5% of patients. 7 The treatment is the same as for infected or bleeding kidney cysts (...) LSD symposium; and Gopala Rangan is a member of the advisory committee on the Safety of Medical Devices and received ?nancial support to attend the KDIGO Controversies on Autosomal Dominant Polycystic Kidney Disease meeting in 2014. * The University of Melbourne, Department of Medicine, Melbourne Health and Northern Health, Melbourne, Australia. † Department of Nephrology, The Royal Melbourne Hospital, Park- ville, Victoria, Australia. ‡ Kidney Health Service and Conjoint Kidney Research

2015 KHA-CARI Guidelines

138. Atrial Fibrillation ? Diagnosis and Management

benefit status for medication coverage and specific medical circumstances of coverage depending on BC PharmaCare plan rules. Diagnostic code: 427.3, I48 2 Use of Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) in Non-Valvular Atrial Fibrillation: Appendix A (2015) Atrial Fibrillation – Diagnosis and Management (2015) 11 Appendices • Appendix A: Types of Atrial Fibrillation • Appendix B: Possible Causes of Atrial Fibrillation • Appendix C: Assessing Atrial (...) approach to the management of clinical problem. We cannot respond to patients or patient advocates requesting advice on issues related to medical conditions. If you need medical advice, please contact a health care professional.Appendix A: Types of Atrial Fibrillation 1,2 Abnormalities or damage to the heart’s structure are the most common cause of atrial fibrillation (AF). Note these types are not exclusive of each other. Valvular AF Occurs in the presence of rheumatic mitral stenosis, a mechanical

2015 Clinical Practice Guidelines and Protocols in British Columbia

139. Breast Cancer Treatment (PDQ®): Health Professional Version

factors for ductal and lobular breast cancer: results from the nurses' health study. Breast Cancer Res 12 (6): R106, 2010. [ ] [ ] Goldacre MJ, Abisgold JD, Yeates DG, et al.: Benign breast disease and subsequent breast cancer: English record linkage studies. J Public Health (Oxf) 32 (4): 565-71, 2010. [ ] [ ] Kabat GC, Jones JG, Olson N, et al.: A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer. Cancer Causes Control 21 (6): 821-8, 2010

2018 PDQ - NCI's Comprehensive Cancer Database

140. Proton Pump Inhibitors for Gastrointestinal Conditions

to 6.8 million person, with incidence of 170,000 per year among adults, and 56,000 in the pediatric population. 5 Besides the gastrointestinal/abdominal symptoms, GERD has also been associated with extra-esophageal symptoms such as cough, hoarseness, laryngeal problems, ear disease, and dental erosion. 4,6 Gastroesophageal reflux disease (GERD) symptoms and sequelae are associated with reduced quality of life, causing considerable morbidity which contribute to substantial medication use and economic (...) with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it be construed as a recommendation for or against the use of a particular health technology. Readers are also cautioned that a lack of good quality evidence does not necessarily mean a lack of effectiveness particularly in the case of new and emerging health technologies, for which little information can be found, but which may

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>